BACKGROUND: Endometriosis is a common gynecological disease characterized by the presence of endometrial tissue outside the uterus causing chronic inflammation, severe pain, and infertility. However, the innate immunity of gamma-delta (γδ) T lymphocytes in endometriosis has not been characterized. Women with endometriosis present numerous endocrine and immune dysfunctions and elevated risk for endometrial, ovarian, and breast cancers. The tyrosine kinase EphA2 is often overexpressed in cancer including endometrial carcinoma. METHODS: We analyzed Vδ1 and Vδ2 γδ T cells in peripheral blood and paired peritoneal fluid samples in endometriosis patients (n = 19) and compared the counts with that of age- and sex-matched healthy donors (n = 33) using flow cytometry. Vδ1 and Vδ2 T cells isolated from healthy donors were used against KLE, RL-95, and Ishikawa endometrial tumor cells in 4 h flow cytometric cytotoxicity assays. The EphA2 blocking studies were performed using antibody, small-molecule inhibitor ALW-II-41-27, and the CRISPR/Cas9. RESULTS: We determined Vδ1 T cells substantially reduced in patients' peripheral blood (p < 0.01) and peritoneal fluid (p < 0.001). No differences were found for circulating Vδ2 T cells compared with peritoneal fluid samples. We observed inherent cytotoxic reactivity of Vδ1 and Vδ2 γδ T lymphocytes against endometrial tumor cells. Importantly, we found reduced specific lysis of EphA2-positive cell lines KLE and RL-95 by Vδ1 T cells in the EphA2 antibody blocking studies and by the EphA2 inhibitor. Furthermore, Vδ1 T-cell-mediated killing was significantly decreased in RL-95 cell EPHA2 knockout. Finally, potent cytolytic activity exerted by Vδ1 T cells was significantly reduced in EPHA2 knockouts in renal A-498 and colon HT-29 carcinoma cell lines. CONCLUSIONS: We determined variable levels of Vδ1 and Vδ2 γδ T cells in endometriosis patients. We observed inherent cytotoxic reactivity of γδ T-cell subsets against endometrial cell lines. Specifically, we found that blocking of EphA2 expression resulted in significant inhibition of endometrial tumor killing mediated by Vδ1 γδ T cells. These results suggest that EphA2 is involved in tumor cell lysis and contributes to susceptibility to Vδ1 γδ T cells cytotoxic reactivity.

Department of Gynecology and Obstetrics University Hospital Brno and Masaryk University Brno Czechia

Faculty of Medicine Department of Pathological Physiology Masaryk University Brno Czechia

Zobrazit více v PubMed

Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG. Immune Interactions in Endometriosis. Expert Rev Clin Immunol (2011) 7:611–26. doi: 10.1586/eci.11.53 PubMed DOI PMC

Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, et al. . World Endometriosis Society Consensus on the Classification of Endometriosis. Hum Reprod (2017) 32:315–24. doi: 10.1093/humrep/dew293 PubMed DOI

Giudice LC. Clinical Practice. Endometriosis. N Engl J Med (2010) 362:2389–98. doi: 10.1056/NEJMcp1000274 PubMed DOI PMC

Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA, Tayade C. IL-17a Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. J Immunol (2015) 195:2591–600. doi: 10.4049/jimmunol.1501138 PubMed DOI PMC

Izumi G, Koga K, Takamura M, Makabe T, Satake E, Takeuchi A, et al. . Involvement of Immune Cells in the Pathogenesis of Endometriosis. J Obstet Gynaecol Res (2018) 44:191–8. doi: 10.1111/jog.13559 PubMed DOI

Suen J-L, Chang Y, Shiu Y-S, Hsu C-Y, Sharma P, Chiu C-C, et al. . IL-10 From Plasmacytoid Dendritic Cells Promotes Angiogenesis in the Early Stage of Endometriosis. J Pathol (2019) 249:485–97. doi: 10.1002/path.5339 PubMed DOI PMC

Wu M-H, Hsiao K-Y, Tsai S-J. Endometriosis and Possible Inflammation Markers. Gynecol Minimally Invasive Ther (2015) 4:61–7. doi: 10.1016/j.gmit.2015.05.001 DOI

Guo S-W, Du Y, Liu X. Platelet-Derived TGF-β1 Mediates the Down-Modulation of NKG2D Expression and may be Responsible for Impaired Natural Killer (NK) Cytotoxicity in Women With Endometriosis. Hum Reprod (2016) 31:1462–74. doi: 10.1093/humrep/dew057 PubMed DOI

Jeung I, Cheon K, Kim M-R. Decreased Cytotoxicity of Peripheral and Peritoneal Natural Killer Cell in Endometriosis. BioMed Res Int (2016) 2016:2916070. doi: 10.1155/2016/2916070 PubMed DOI PMC

Kang Y-J, Jeung IC, Park A, Park Y-J, Jung H, Kim T-D, et al. . An Increased Level of IL-6 Suppresses NK Cell Activity in Peritoneal Fluid of Patients With Endometriosis via Regulation of SHP-2 Expression. Hum Reprod (2014) 29:2176–89. doi: 10.1093/humrep/deu172 PubMed DOI

Thiruchelvam U, Wingfield M, O’Farrelly C. Natural Killer Cells: Key Players in Endometriosis. Am J Reprod Immunol (2015) 74:291–301. doi: 10.1111/aji.12408 PubMed DOI

Yu J-J, Sun H-T, Zhang Z-F, Shi R-X, Liu L-B, Shang W-Q, et al. . IL15 Promotes Growth and Invasion of Endometrial Stromal Cells and Inhibits Killing Activity of NK Cells in Endometriosis. Reproduction (2016) 152:151–60. doi: 10.1530/REP-16-0089 PubMed DOI

Greaves E, Temp J, Esnal-Zufiurre A, Mechsner S, Horne AW, Saunders PTK. Estradiol Is a Critical Mediator of Macrophage-Nerve Cross Talk in Peritoneal Endometriosis. Am J Pathol (2015) 185:2286–97. doi: 10.1016/j.ajpath.2015.04.012 PubMed DOI PMC

Hogg C, Horne AW, Greaves E. Endometriosis-Associated Macrophages: Origin, Phenotype, and Function. Front Endocrinol (2020) 11:7. doi: 10.3389/fendo.2020.00007 PubMed DOI PMC

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013 PubMed DOI

Lu KH, Broaddus RR. Endometrial Cancer. N Engl J Med (2020) 383:2053–64. doi: 10.1056/NEJMra1514010 PubMed DOI

Shaw E, Farris M, McNeil J, Friedenreich C. Obesity and Endometrial Cancer. Recent Results Cancer Res (2016) 208:107–36. doi: 10.1007/978-3-319-42542-9_7 PubMed DOI

Hayday AC. [Gamma][Delta] Cells: A Right Time and a Right Place for a Conserved Third Way of Protection. Annu Rev Immunol (2000) 18:975–1026. doi: 10.1146/annurev.immunol.18.1.975 PubMed DOI

Vantourout P, Hayday A. Six-Of-the-Best: Unique Contributions of γδ T Cells to Immunology. Nat Rev Immunol (2013) 13:88–100. doi: 10.1038/nri3384 PubMed DOI PMC

Chien Y, Meyer C, Bonneville M. γδ T Cells: First Line of Defense and Beyond. Annu Rev Immunol (2014) 32:121–55. doi: 10.1146/annurev-immunol-032713-120216 PubMed DOI

Silva-Santos B, Strid J. γδ T Cells Get Adaptive. Nat Immunol (2017) 18:370–2. doi: 10.1038/ni.3705 PubMed DOI

Fichtner AS, Ravens S, Prinz I. Human γδ TCR Repertoires in Health and Disease. Cells (2020) 9:800. doi: 10.3390/cells9040800 PubMed DOI PMC

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. . The Prognostic Landscape of Genes and Infiltrating Immune Cells Across Human Cancers. Nat Med (2015) 21:938–45. doi: 10.1038/nm.3909 PubMed DOI PMC

Walker-Daniels J, Hess AR, Hendrix MJC, Kinch MS. Differential Regulation of EphA2 in Normal and Malignant Cells. Am J Pathol (2003) 162:1037–42. doi: 10.1016/S0002-9440(10)63899-0 PubMed DOI PMC

Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. . Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers. Clin Chem (2004) 50:490–9. doi: 10.1373/clinchem.2003.026849 PubMed DOI

Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells. Cancer Res (2001) 61:2301–6. PubMed

Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, et al. . Over-Expression of Eph and Ephrin Genes in Advanced Ovarian Cancer: Ephrin Gene Expression Correlates With Shortened Survival. BMC Cancer (2006) 6:144. doi: 10.1186/1471-2407-6-144 PubMed DOI PMC

Lee J-W, Stone RL, Lee SJ, Nam EJ, Roh J-W, Nick AM, et al. . EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. Clin Cancer Res (2010) 16:2562–70. doi: 10.1158/1078-0432.CCR-10-0017 PubMed DOI PMC

Merritt WM, Kamat AA, Hwang J-Y, Bottsford-Miller J, Lu C, Lin YG, et al. . Clinical and Biological Impact of EphA2 Overexpression and Angiogenesis in Endometrial Cancer. Cancer Biol Ther (2010) 10:1306–14. doi: 10.4161/cbt.10.12.13582 PubMed DOI PMC

Harly C, Joyce SP, Domblides C, Bachelet T, Pitard V, Mannat C, et al. . Human γδ T Cell Sensing of AMPK-Dependent Metabolic Tumor Reprogramming Through TCR Recognition of Epha2. Sci Immunol (2021) 6:eaba9010. doi: 10.1126/sciimmunol.aba901 PubMed DOI

Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 Gamma-Delta T Cells Exert Potent Specific Cytotoxicity Against Primary Multiple Myeloma Cells. Cytotherapy (2012) 14:1110–8. doi: 10.3109/14653249.2012.700766 PubMed DOI

Vallvé-Juanico J, Houshdaran S, Giudice LC. The Endometrial Immune Environment of Women With Endometriosis. Hum Reprod Update (2019) 25:564–91. doi: 10.1093/humupd/dmz018 PubMed DOI PMC

Presti EL, Dieli F, Fourniè JJ, Meraviglia S. Deciphering Human γδ T Cell Response in Cancer: Lessons From Tumor-Infiltrating γδ T Cells. Immunol Rev (2020) 298:153–64. doi: 10.1111/imr.12904 PubMed DOI

Silva-Santos B, Serre K, Norell H. γδ T Cells in Cancer. Nat Rev Immunol (2015) 15:683–91. doi: 10.1038/nri3904 PubMed DOI

Deniger DC, Moyes JS, Cooper LJN. Clinical Applications of Gamma Delta T Cells With Multivalent Immunity. Front Immunol (2014) 5:636. doi: 10.3389/fimmu.2014.00636 PubMed DOI PMC

Lo Presti E, Corsale AM, Dieli F, Meraviglia S. γδ Cell-Based Immunotherapy for Cancer. Expert Opin Biol Ther (2019) 19:887–95. doi: 10.1080/14712598.2019.1634050 PubMed DOI

Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating Gammadelta (γδ) T Cells and Their Receptors Into Cancer Cell Therapies. Nat Rev Drug Discov (2020) 19:169–84. doi: 10.1038/s41573-019-0038-z PubMed DOI

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. . The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clin Cancer Res (2009) 15:5323–37. doi: 10.1158/1078-0432.CCR-09-0737 PubMed DOI PMC

Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in Cancer. J Hematol Oncol (2020) 13:114. doi: 10.1186/s13045-020-00944-9 PubMed DOI PMC

Noberini R, Lamberto I, Pasquale EB. Targeting Eph Receptors With Peptides and Small Molecules: Progress and Challenges. Semin Cell Dev Biol (2012) 23:51–7. doi: 10.1016/j.semcdb.2011.10.023 PubMed DOI PMC

Tandon M, Vemula SV, Mittal SK. Emerging Strategies for EphA2 Receptor Targeting for Cancer Therapeutics. Expert Opin Ther Targets (2011) 15:31–51. doi: 10.1517/14728222.2011.538682 PubMed DOI PMC

Wykosky J, Debinski W. The EphA2 Receptor and Ephrina1 Ligand in Solid Tumors: Function and Therapeutic Targeting. Mol Cancer Res (2008) 6:1795–806. doi: 10.1158/1541-7786.MCR-08-0244 PubMed DOI PMC

Landen CN, Kinch MS, Sood AK. EphA2 as a Target for Ovarian Cancer Therapy. Expert Opin Ther Targets (2005) 9:1179–87. doi: 10.1517/14728222.9.6.1179 PubMed DOI

Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, et al. . EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res (2016) 76:305–18. doi: 10.1158/0008-5472.CAN-15-0717 PubMed DOI PMC

Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, et al. . EphA2 Overexpression Is Associated With Lack of Hormone Receptor Expression and Poor Outcome in Endometrial Cancer. Cancer (2009) 115:2684–92. doi: 10.1002/cncr.24335 PubMed DOI PMC

Charmsaz S, Beckett K, Smith FM, Bruedigam C, Moore AS, Al-Ejeh F, et al. . EphA2 Is a Therapy Target in EphA2-Positive Leukemias But Is Not Essential for Normal Hematopoiesis or Leukemia. PLoS One (2015) 10:e0130692. doi: 10.1371/journal.pone.0130692 PubMed DOI PMC